The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study
Open accessAbstract
BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) protects against key serotypes that increased after routine immunisation with the seven-valent vaccine (PCV7), but its potential for herd protection and serotype replacement is uncertain. The aim of this study was to analyse the effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction. METHODS: We used a national dataset of electronically reported and serotyped invasive pneumococcal disease cases in England and Wales to estimate incidence rate ratios (IRRs) for vaccine and non-vaccine type invasive pneumococcal disease between July, 2013, and June, 2014, versus the pre-PCV13 and pre-PCV7 baseline. Incidence rates were corrected for missing serotype data and changes in surveillance sensitivity over time. An over-dispersed Poisson model was used to estimate IRRs and confidence intervals. FINDINGS: Incidence of invasive pneumococcal disease in the epidemiological year 2013/14 decreased by 32% compared with the pre-PCV13 baseline (incidence 10·14 per 100,000 in 2008-10 vs 6·85 per 100,000 in 2013/14; IRR 0·68, 95% CI 0·64-0·72). This was due to an 86% reduction of the serotypes covered by PCV7 (1·46 vs 0·20 per 100,000; IRR 0·14, 0·10-0·18) and a 69% reduction of the additional six serotypes covered by PCV13 (4·48 vs 1·40 per 100,000; IRR 0·31, 0·28-0·35). When compared with the pre-PCV7 baseline, there was a 56% overall reduction in invasive pneumococcal disease (15·63 vs 6·85 per 100,000; IRR 0·44, 95% CI 0·43-0·47). Compared with the pre-PCV13 baseline, the incidence of non-PCV13 serotypes increased (incidence all ages 4·19 vs 5·25 per 100,000; IRR 1·25, 95% CI 1·17-1·35) due to increases across a broad range of serotypes in children younger than 5 years and in people aged 45 years or more. In children younger than 5 years, incidence of non-PCV13 serotypes in 2013/14 was higher than in 2012/13 (age <2 years: 12·03 vs 10·83 per 100,000; age 2-4 years: 4·08 vs 3·63 per 100,000). INTERPRETATION: 8 years of PCV use in England and Wales has reduced the overall incidence of invasive pneumococcal disease by more than 50%. The herd protection induced by PCV7 is continuing, and similar indirect protection is occurring from the additional serotypes covered by PCV13. There is, however, evidence of increasing invasive pneumococcal disease due to non-PCV13 serotypes, particularly in children younger than 5 years in 2014. If this increase continues, the maximum benefit of the PCV13 programme in children might already have been achieved. FUNDING: Public Health England funds national surveillance of invasive pneumococcal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A 56% reduction in invasive pneumococcal disease (IPD) among adults has been reported since the introduction of the PCV7 into the routine infant schedule and its replacement by PCV13 in April 2010.8”
From Community-acquired acute bacterial meningitis in adults: a clinical update (2019) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Brien, K. L., Wolfson, L. J., Watt, J. P., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O. S., & Cherian, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61204-6 · Cited by 2,398
Serotype replacement in disease after pneumococcal vaccination
Weinberger, D. M., Malley, R., & Lipsitch, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62225-8 · Cited by 1,020
Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H., Reingold, A., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71081-3 · Cited by 733
Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P., & George, R. C. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70090-1 · Cited by 643
Self-citationAndrews, N. J., Waight, P. A., Burbidge, P., Pearce, E., Roalfe, L., Zancolli, M., Slack, M., Ladhani, S. N., Miller, E., & Goldblatt, D. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70822-9 · Cited by 545
Self-citationFeikin, D. R., Kagucia, E. W., Loo, J. D., Link-Gelles, R., Puhan, M. A., Cherian, T., Levine, O. S., Whitney, C. G., O’Brien, K. L., Moore, M. R., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001517 · Cited by 470
Flasche, S., Van Hoek, A. J., Sheasby, E., Waight, P., Andrews, N., Sheppard, C., George, R., & Miller, E. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001017 · Cited by 277
Self-citationvan Hoek, A. J., Andrews, N., Waight, P. A., Stowe, J., Gates, P., George, R., & Miller, E. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.02.017 · Cited by 253
Self-citationAndrews, N. J., Waight, P. A., George, R. C., Slack, M. P. E., & Miller, E. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.09.019 · Cited by 239
Self-citationCooper, D., Yu, X., Sidhu, M., Nahm, M. H., Fernsten, P., & Jansen, K. U. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.06.056 · Cited by 223
Research works printed but not linked: 3
- Roca, 2014, Effect of replacing PCV-7 with PCV-13 in the expanded program of immunization on nasopharyngeal carriage of pneumococci in the Gambia, Pneumonia, 3, 20
- Nunes, 2014, Acquisition of Streptococcus pneumoniae in South African children vaccinated with 7-valent pneumococcal conjugate vaccine (PCV7), Pneumonia, 3, 44
- Moore M, Link-Gelles R, Guevara R, et al. Case-control study of effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) against Invasive Pneumococcal Disease (IPD) in the US: preliminary estimates. International Symposium on Pneumococci and Pneumococcal Diseases; Hyderabad, India; March 9–13, 2014. Poster 032.
Cited by
Wahl, B., O'Brien, K. L., Greenbaum, A., Majumder, A., Liu, L., Chu, Y., Lukšić, I., Nair, H., McAllister, D. A., Campbell, H., et al. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30247-x · Cited by 1,118
Ladhani, S. N., Collins, S., Djennad, A., Sheppard, C. L., Borrow, R., Fry, N. K., Andrews, N. J., Miller, E., & Ramsay, M. E. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30052-5 · Cited by 559
Self-citationBalsells, E., Guillot, L., Nair, H., & Kyaw, M. H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177113 · Cited by 393
Köhler, J. R., Hube, B., Puccia, R., Casadevall, A., & Perfect, J. R. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0014-2016 · Cited by 297
Acute bacterial meningitis in adults
McGill, F., Heyderman, R. S., Panagiotou, S., Tunkel, A. R., & Solomon, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30654-7 · Cited by 274
Metadata
- Authors
- Waight, P. A., Andrews, N. J., Ladhani, S. N., Sheppard, C. L., Slack, M. P. E., & Miller, E.
- Affiliations
- Public Health England (GB)
- Griffith University (AU)
- Corresponding author
- Waight, Pauline A
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 15
- Issue
- 5
- Pages
- 535-543
- ISSN
- 1473-3099 (ISSN-L)
- PMC
- PMC7130081
- OpenAlex
- W2025200855
- Cited by
- 589
- References
- 24
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 32 · 2023: 35 · 2022: 40 · 2021: 51 · 2020: 46 · 2019: 69 · 2018: 86 · 2017: 90 · 2016: 61 · 2015: 30
- FWCI
- 69.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Griffith Research Online (submittedVersion, cc-by-nc-nd)
- Funders
- Public Health England
- Topics
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Microbiology › Microbial infections and disease research
- Keywords
- 13-valent pneumococcal conjugate vaccine, PCV13, invasive pneumococcal disease, Streptococcus pneumoniae, serotype replacement, herd protection, PCV7, vaccine impact, England and Wales, incidence rate ratio, overdispersion
- MeSH terms
- Adolescent, Adult, Aged, Child, Child, Preschool, England, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Pneumococcal Infections, Streptococcus pneumoniae, Wales, Incidence, Poisson Distribution, Vaccines, Conjugate, Pneumococcal Vaccines, Mass Vaccination, Epidemiological Monitoring, Serogroup
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. https://app.cochat.ai/papers/10.1016/s1473-3099(15)70044-7
- The paper
- Waight, P. A., Andrews, N. J., Ladhani, S. N., Sheppard, C. L., Slack, M. P. E., & Miller, E. (2015). Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(15)70044-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.